Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Trading Statement

2nd Apr 2009 11:41

RNS Number : 0038Q
Omega Diagnostics Group PLC
02 April 2009
 



Omega Diagnostics Group Plc 

("Omega")

Trading Update

Omega, the AIM listed medical diagnostics company, announces that revenue for the year ended 31 March 2009 is £5.44m, some 56% ahead of last year's figure (31 March 2008: £3.49m). On a full like for like basis, turnover has increased by 20% combined, and individually across all three trading entities, where the figures in brackets for Genesis Diagnostics and Cambridge Nutritional Sciences represent the full 12-month comparative:

31 March 2009

31 March 2008

% increase

Omega Diagnostics (ODL)

£2.28m

£2.08m

+9.5%

Genesis Diagnostics

£2.51m

£1.07m (£1.90m)

+133.9% (+32.6%)

Cambridge Nutritional Sciences

£0.65m

£0.34m (£0.56m)

+93.9% (+16.5%)

TOTAL

£5.44m

£3.49m (£4.54m)

+55.9% (+20.0%)

ODL has seen growth in most of its regions around the world, particularly in Africa/Middle East and Asian regions. Genesis has seen growth fuelled mainly by the roll-out into a number of territories of its microarray-based Genarrayt™ assay system for food intolerance, where evaluations are on-going which are expected to lead to increased sales of reagent kits going forward. CNS has benefited from launching the Food Detective™ kit into a number of European territories and from an increase in sales from its Foodprint™ laboratory testing service.

Profit before tax (and before share based payments, exceptional costs and amortisation of intangible assets) is expected to be in line with market expectations. 

The outlook for the new financial year is encouraging as we expect to continue to widen the roll-out of the Genarrayt™ system and to launch Food Detective™ into other new markets and we look forward to providing an update on progress when the full year results are announced in early July 2009.

Further enquiries:

Omega Diagnostics Plc

Tel: 01259 763 030

Andrew Shepherd, Chief Executive

Kieron Harbinson, Group Finance Director

www.omegadiagnostics.com

Cenkos Securities plc

Tel: 020 7397 8900

Nick Wells

Andy Roberts

Elizabeth Bowman

Parkgreen Communications Limited

Tel: 020 7933 8787

Paul McManus

Mob: 07980 541 893

[email protected]

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTFGGGDGZLGLZM

Related Shares:

ODX.L
FTSE 100 Latest
Value8,446.70
Change31.45